Insufficient· Insufficient EvidenceNarrative Review

Cell-Based Therapies for Post-Traumatic Ankle Osteoarthritis and Osteochondral Lesions of the Talus: A Systematic Scoping Review of an Emerging and Heterogeneous Evidence Base.

Jeon SY., Kim MW., Lee DH.

Narrative Review on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, Ankle Injury, published in Bioengineering (Basel) (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type: Narrative Review
Journal: Bioengineering (Basel) (2026)
Country: Switzerland
Reported sample size: —
PMID: 42510508
DOI: 10.3390/bioengineering13070843

Abstract (original English)

Background : Ankle osteoarthritis (OA) differs fundamentally from knee OA: it is predominantly post-traumatic, affects younger and more active patients, and frequently arises from focal osteochondral lesions of the talus (OCLT) rather than diffuse degeneration. Cell-based and orthobiologic therapies-bone marrow aspirate concentrate (BMAC), bone marrow-derived cell transplantation (BMDC), adipose-derived mesenchymal stromal cells (ADMSCs), stromal vascular fraction (SVF), micro-fragmented adipose tissue (mFAT), and peripheral blood-derived products-have been proposed as joint-preserving options, but the evidence base has not been mapped in a way that separates degenerative post-traumatic ankle OA from focal chondral repair, or that distinguishes cells given as a standalone injection from cells given alongside a therapeutic operation. Methods : We conducted a systematic scoping review following the PRISMA-ScR framework. Human clinical studies applying cell-based therapies to post-traumatic ankle OA and/or OCLT were charted by population, cell source and preparation, mode of delivery, concomitant procedures, follow-up, and reported clinical and structural outcomes. Mode of delivery-standalone intra-articular injection versus adjunct to a concomitant surgical procedure-was pre-specified as a primary analytic axis, because it determines whether an observed effect can be attributed t

What this study does not prove

• This study does not prove SVF is an approved treatment or a replacement for standard care.
• This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

There is currently not enough data to draw conclusions about benefit or risk for this topic.

How we grade evidence

Knee Ankle & Foot Knee Osteoarthritis Osteoarthritis Cartilage Damage Ankle Injury

View on PubMed DOI

Cell-Based Therapies for Post-Traumatic Ankle Osteoarthritis and Osteochondral Lesions of the Talus: A Systematic Scoping Review of an Emerging and Heterogeneous Evidence Base.

Abstract (original English)

What this study does not prove

Evidence level

Related research

Adipose-Derived Cell Therapies Versus Nonactive Controls for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Clinical Outcomes of Biologic Therapies for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Studies With ≥12-Month Follow-up.

Intra-articular fat grafting for pain relief and functioning improvement in patients with knee osteoarthritis: systematic review.

Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.

Intra-articular adipose-derived cell therapies for knee osteoarthritis: a systematic review of randomized controlled trials.

Total Knee Arthroplasty versus Mesenchymal Stem Cell Therapy for Moderate Knee Osteoarthritis: An Umbrella Analysis of Clinical Outcomes, Quality of Life, and Safety.